prolgolimab   Click here for help

GtoPdb Ligand ID: 12991

Synonyms: BCD-100 | BCD100
Immunopharmacology Ligand
Compound class: Antibody
Comment: Prolgolimab (BCD-100) is a chimeric IgG1 anti-programmed cell death 1 (PD-1) monoclonal antibody [1]. It acts as an inhibitor of the PD-1/PD-L1-PD-L2 inhibitory immune checkpoint. The design of prolgolimab abolishes FcγR binding and therefore Fc-mediated effector functions (antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity).
Click here for help
No information available.
Summary of Clinical Use Click here for help
Prolgolimab (BCD-100) is in advanced clinical development for the treatment of advanced solid tumours. The fixed dose combination of prolgolimab (BCD-100) and nurulimab (BCD-145), BCD-217, has progressed to phase 3 clinical trials for advanced melanoma.
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT03912389 Efficacy and Safety of BCD-100 (Anti-PD-1) in Combination With Platinum-Based Chemotherapy as First Line Treatment in Patients With Advanced Non-Squamous NSCLC Phase 3 Interventional Biocad
NCT03912415 Efficacy and Safety of BCD-100 (Anti-PD-1) in Combination With Platinum-Based Chemotherapy With and Without Bevacizumab as First-Line Treatment of Subjects With Advanced Cervical Cancer (FERMATA) Phase 3 Interventional Biocad
NCT05732805 A Clinical Study of BCD-217 (Nurulimab + Prolgolimab) Followed by Anti-PD-1 Compared to Anti-PD-1 Monotherapy as First-Line Treatment in Subjects With Unresectable/Metastatic Melanoma Phase 3 Interventional Biocad
NCT03269565 International Trial of the Efficacy and Safety of BCD-100 in Patients With Melanoma Phase 2 Interventional Biocad 2